Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

CADL

Candel Therapeutics Inc

Last Close
May 31 • 04:00PM ET
8.90
Dollar change
+0.28
Percentage change
3.25 		%
Held by: VTI VXF IWC AVSC Scroll to Statements
Index- P/E- EPS (ttm)-1.29 Insider Own42.60% Shs Outstand29.21M Perf Week-16.74%
Market Cap264.69M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float17.07M Perf Month11.53%
Income-37.37M PEG- EPS next Q- Inst Own5.11% Short Float4.96% Perf Quarter423.53%
Sales0.00M P/S- EPS this Y- Inst Trans-0.70% Short Ratio0.15 Perf Half Y934.88%
Book/sh0.20 P/B43.69 EPS next Y- ROA-75.90% Short Interest0.85M Perf Year489.40%
Cash/sh0.86 P/C10.30 EPS next 5Y- ROE-163.77% 52W Range0.66 - 14.30 Perf YTD505.44%
Dividend Est.- P/FCF- EPS past 5Y-46.75% ROI-222.80% 52W High-37.76% Beta-0.87
Dividend TTM- Quick Ratio2.00 Sales past 5Y-25.00% Gross Margin-3654.84% 52W Low1248.48% ATR (14)1.39
Dividend Ex-Date- Current Ratio2.00 EPS Y/Y TTM-39.34% Oper. Margin0.00% RSI (14)49.47 Volatility19.04% 16.53%
Employees42 Debt/Eq3.53 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price11.00
Option/ShortYes / No LT Debt/Eq1.80 EPS Q/Q7.40% Payout- Rel Volume0.11 Prev Close8.62
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsMay 14 BMO Avg Volume5.67M Price8.90
SMA20-12.91% SMA5029.65% SMA200240.61% Trades Volume626,352 Change3.25%
Date Action Analyst Rating Change Price Target Change
Dec-02-22Initiated H.C. Wainwright Buy $11
Nov-19-21Initiated BMO Capital Markets Outperform $18
Aug-23-21Initiated UBS Buy $9
Aug-23-21Initiated Jefferies Buy $22
Aug-23-21Initiated Credit Suisse Outperform $15
May-30-24 08:00AM
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
(GlobeNewswire)
May-28-24 11:07AM
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
(Zacks) +9.62%
May-24-24 11:42AM
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
(Zacks) -27.03%
May-23-24 05:00PM
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
(GlobeNewswire)
11:51AM
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates
(PR Newswire)
08:00AM Loading…
May-22-24 08:00AM
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire) -13.77%
May-20-24 08:00AM
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
(GlobeNewswire)
May-15-24 11:14AM
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
(PR Newswire) +30.84%
May-14-24 01:53PM
CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024
(InvestorPlace)
08:00AM
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
May-09-24 10:26AM
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
(PR Newswire) -7.94%
Apr-25-24 08:00AM
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
(GlobeNewswire) +6.28%
Apr-12-24 10:00AM
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
(Zacks) -8.52%
Apr-11-24 09:00AM
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
(GlobeNewswire) +42.75%
Apr-09-24 08:00AM
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
(GlobeNewswire) -20.84%
12:10PM Loading…
Apr-05-24 12:10PM
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
(Zacks)
Apr-04-24 12:24PM
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
(Benzinga) +280.95%
08:00AM
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
(GlobeNewswire)
Mar-28-24 04:05PM
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
(GlobeNewswire)
01:53PM
CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023
(InvestorPlace)
08:05AM
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Mar-15-24 08:15AM
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
(News Direct)
Mar-06-24 08:00AM
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
(Newsfile)
Mar-05-24 04:30PM
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
(GlobeNewswire)
Feb-13-24 07:30AM
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
(GlobeNewswire) +29.50%
Feb-05-24 08:00AM
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
(GlobeNewswire)
Dec-13-23 12:21PM
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
(Zacks) +17.82%
Dec-12-23 08:00AM
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
(GlobeNewswire) +16.29%
Nov-28-23 09:00AM
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN Discovery Platform, and Key Clinical Readouts for CAN-2409
(GlobeNewswire) -8.16%
Nov-09-23 09:43AM
Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress
(GuruFocus.com) -13.00%
08:00AM Loading…
08:00AM
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Nov-04-23 08:00AM
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN Discovery Platform at SITC
(GlobeNewswire)
Nov-03-23 12:00PM
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
(GlobeNewswire) -21.50%
Oct-18-23 11:00AM
Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110
(GlobeNewswire)
Sep-27-23 09:40AM
Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
(GlobeNewswire) -9.00%
Sep-26-23 08:00AM
Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer
(GlobeNewswire) -10.71%
Sep-06-23 08:00AM
Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-10-23 08:00AM
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Aug-02-23 08:00AM
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
(GlobeNewswire)
Jun-13-23 08:00AM
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
(GlobeNewswire)
Jun-08-23 08:00AM
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
(GlobeNewswire) +5.30%
Jun-05-23 08:00AM
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
(GlobeNewswire) +9.80%
May-22-23 08:26AM
Favourable Signals For Candel Therapeutics: Numerous Insiders Acquired Stock \
(Simply Wall St.) +7.64%
May-19-23 01:51PM
Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer
(Benzinga) -8.15%
09:00AM
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
(GlobeNewswire)
May-11-23 08:00AM
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
May-02-23 08:00AM
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
(GlobeNewswire) +15.44%
Apr-17-23 08:00AM
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
(GlobeNewswire) +19.01%
Mar-30-23 08:00AM
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Mar-08-23 06:30AM
Daily Vickers Top Insider Picks for 03/08/2023
(Argus Research) +5.54%
Mar-07-23 06:34AM
Daily Vickers Top Insider Picks for 03/07/2023
(Argus Research) +6.46%
Mar-06-23 07:22AM
Daily Vickers Top Insider Picks for 03/06/2023
(Argus Research)
Mar-03-23 06:38AM
Daily Vickers Top Insider Picks for 03/03/2023
(Argus Research)
Mar-02-23 06:44AM
Daily Vickers Top Insider Picks for 03/02/2023
(Argus Research)
Mar-01-23 06:01AM
Daily Vickers Top Insider Picks for 03/01/2023
(Argus Research)
Feb-28-23 06:43AM
Daily Vickers Top Insider Picks for 02/28/2023
(Argus Research) -9.01%
Feb-27-23 06:50AM
Daily Vickers Top Insider Picks for 02/27/2023
(Argus Research)
Feb-24-23 07:17AM
Daily Vickers Top Insider Picks for 02/24/2023
(Argus Research)
Feb-23-23 07:21AM
Daily Vickers Top Insider Picks for 02/23/2023
(Argus Research)
Feb-22-23 06:56AM
Daily Vickers Top Insider Picks for 02/22/2023
(Argus Research) -5.28%
Feb-21-23 07:35AM
Daily Vickers Top Insider Picks for 02/21/2023
(Argus Research)
Feb-17-23 06:27AM
Daily Vickers Top Insider Picks for 02/17/2023
(Argus Research)
Feb-16-23 07:28AM
Daily Vickers Top Insider Picks for 02/16/2023
(Argus Research)
Feb-15-23 07:01AM
Daily Vickers Top Insider Picks for 02/15/2023
(Argus Research)
Feb-14-23 06:23AM
Daily Vickers Top Insider Picks for 02/14/2023
(Argus Research)
Feb-13-23 07:30AM
Daily Vickers Top Insider Picks for 02/13/2023
(Argus Research)
Feb-10-23 06:42AM
Daily Vickers Top Insider Picks for 02/10/2023
(Argus Research) -8.86%
Feb-09-23 06:51AM
Daily Vickers Top Insider Picks for 02/09/2023
(Argus Research)
Feb-08-23 06:45AM
Daily Vickers Top Insider Picks for 02/08/2023
(Argus Research)
Feb-07-23 06:46AM
Daily Vickers Top Insider Picks for 02/07/2023
(Argus Research)
Feb-06-23 06:56AM
Daily Vickers Top Insider Picks for 02/06/2023
(Argus Research) -6.20%
Feb-03-23 06:32AM
Daily Vickers Top Insider Picks for 02/03/2023
(Argus Research)
Feb-02-23 06:43AM
Daily Vickers Top Insider Picks for 02/02/2023
(Argus Research)
Feb-01-23 08:00AM
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
(GlobeNewswire) -6.21%
06:14AM
Daily Vickers Top Insider Picks for 02/01/2023
(Argus Research)
Jan-31-23 06:50AM
Daily Vickers Top Insider Picks for 01/31/2023
(Argus Research) +6.62%
Jan-30-23 06:42AM
Daily Vickers Top Insider Picks for 01/30/2023
(Argus Research) -9.74%
Jan-27-23 07:00AM
Daily Vickers Top Insider Picks for 01/27/2023
(Argus Research) +6.80%
Jan-26-23 06:44AM
Daily Vickers Top Insider Picks for 01/26/2023
(Argus Research) +6.16%
Jan-25-23 06:39AM
Daily Vickers Top Insider Picks for 01/25/2023
(Argus Research) -11.80%
Jan-24-23 06:48AM
Daily Vickers Top Insider Picks for 01/24/2023
(Argus Research)
Jan-23-23 06:58AM
Daily Vickers Top Insider Picks for 01/23/2023
(Argus Research) +14.29%
Jan-20-23 06:55AM
Daily Vickers Top Insider Picks for 01/20/2023
(Argus Research) +5.77%
Jan-19-23 06:43AM
Daily Vickers Top Insider Picks for 01/19/2023
(Argus Research) +8.18%
Jan-18-23 06:28AM
Daily Vickers Top Insider Picks for 01/18/2023
(Argus Research) -5.45%
Jan-17-23 06:27AM
Daily Vickers Top Insider Picks for 01/17/2023
(Argus Research) +5.77%
Jan-13-23 06:56AM
Daily Vickers Top Insider Picks for 01/13/2023
(Argus Research) +5.58%
Jan-12-23 08:00AM
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
(GlobeNewswire)
06:50AM
Daily Vickers Top Insider Picks for 01/12/2023
(Argus Research)
Jan-11-23 06:53AM
Daily Vickers Top Insider Picks for 01/11/2023
(Argus Research) +10.34%
Jan-09-23 06:31AM
Daily Vickers Top Insider Picks for 01/09/2023
(Argus Research)
Jan-06-23 06:49AM
Daily Vickers Top Insider Picks for 01/06/2023
(Argus Research) -10.41%
Jan-04-23 06:54AM
Daily Vickers Top Insider Picks for 01/04/2023
(Argus Research) +12.43%
Jan-03-23 06:26AM
Daily Vickers Top Insider Picks for 01/03/2023
(Argus Research)
Dec-30-22 07:17AM
Daily Vickers Top Insider Picks for 12/30/2022
(Argus Research) +7.83%
Dec-29-22 06:51AM
Daily Vickers Top Insider Picks for 12/29/2022
(Argus Research) +8.50%
Dec-28-22 06:58AM
Daily Vickers Top Insider Picks for 12/28/2022
(Argus Research)
Dec-27-22 07:11AM
Daily Vickers Top Insider Picks for 12/27/2022
(Argus Research)
Dec-23-22 06:32AM
Daily Vickers Top Insider Picks for 12/23/2022
(Argus Research) -12.14%
Dec-22-22 06:34AM
Daily Vickers Top Insider Picks for 12/22/2022
(Argus Research) +7.45%
Candel Therapeutics, Inc. is a late clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.